about
MIP-Based Sensors: Promising New Tools for Cancer Biomarker Determination.Weight change therapy as a potential treatment for end-stage ovarian carcinoma.Comparative secretome of ovarian serous carcinoma: Gelsolin in the spotlightDoxycycline inducible Krüppel-like factor 4 lentiviral vector mediates mesenchymal to epithelial transition in ovarian cancer cells.Down-regulated aquaporin 5 inhibits proliferation and migration of human epithelial ovarian cancer 3AO cellsIn vivo phage display selection of an ovarian cancer targeting peptide for SPECT/CT imaging.Urinary interleukin-1β levels among gynecological patients.Protein glycosylation in cancer.Overexpression of CUEDC2 Predicts Poor Prognosis in Ovarian Serous Carcinomas.Well-defined single polymer nanoparticles for the antibody-targeted delivery of chemotherapeutic agents.Promoting gynecologic cancer awareness at a critical juncture--where women and providers meet.ShRNA-mediated silencing of the RFC3 gene suppress ovarian tumor cells proliferation.Prognostic value of MMP-2 for patients with ovarian epithelial carcinoma: a systematic review and meta-analysis.Intended care seeking for ovarian cancer symptoms among U.S. womenOvarian and breast cancer spheres are similar in transcriptomic features and sensitive to fenretinide.Comorbidity and survival of Danish ovarian cancer patients from 2000-2011: a population-based cohort study.Current approaches and challenges in managing and monitoring treatment response in ovarian cancer.Loss of expression of EphB1 protein in serous carcinoma of ovary associated with metastasis and poor survival.A longitudinal analysis with CA-125 to predict overall survival in patients with ovarian cancer.The role of Rho GTPase in cell stiffness and cisplatin resistance in ovarian cancer cells.Thyroid hormones derivatives reduce proliferation and induce cell death and DNA damage in ovarian cancer.Evaluation of the Time-Varying Effect of Prognostic Factors on Survival in Ovarian Cancer.Dysregulation of AKT3 along with a small panel of mRNAs stratifies high-grade serous ovarian cancer from both normal epithelia and benign tumor tissues.Is serum human epididymis protein 4 ready for prime time?
P2860
Q30356800-B3B51D01-0517-4BE1-BBB0-365F38F7BE34Q33629673-2C38E158-5CE4-4ECD-9F55-316870A06C45Q33751321-C7A2A183-24E0-4D36-B696-221DCA073323Q34066627-5D9FA692-AB3B-4127-B4DC-A3E51E6013D1Q34185010-CAE8850F-31B0-4C91-954C-F9DD1699D8D1Q34228815-0A1AB7C3-1D04-4DE8-BB34-73EE2DDDA5E3Q34584672-A56BC2D3-2A43-465E-92ED-5B251D1CA63DQ35413473-D12FE8F5-2DA9-447F-813A-B5E2B68C31C8Q35631627-369774B1-D045-4D46-BBAA-A2405DD14E65Q35751371-7936B244-2230-45BD-B224-193FAD90D80CQ35775856-E1D4D05C-7E18-44E4-A080-6E046842586AQ36095110-3071C224-60E5-4287-9BA8-C1CAAE07832FQ36229126-D64B6DCB-E154-4106-BDC1-2F033BD2ADD0Q37056782-C6ECBE1B-09BF-437C-80BA-6E84011077CBQ37275730-EB9F5310-9122-43BE-B745-6AC93078FF7CQ37322464-F1E3DDE8-39C8-4088-B114-C4E25D29319BQ37435187-A1E0FB47-CE0D-49BE-9137-762FE32A9B57Q37452286-BAF0FCB5-B12A-4827-9B90-2496F6D702CBQ37486159-EBEB46C8-8A5E-4653-B8B3-8A953D3B835DQ39005778-57ECBED5-BE70-4862-AE7E-3923CF2B6DACQ47354681-3955A7D1-0E06-4368-B27F-7A5A1F6FDCA4Q48095261-F9C17FDD-4021-4A8E-BA3C-4A37CC8DC9A9Q49163347-32DDDAFA-127D-4A59-8C1A-4553CA7865BAQ50773867-CB732C2B-ECBB-4B63-B301-F32E846A0F39
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Detection and monitoring of ovarian cancer.
@en
type
label
Detection and monitoring of ovarian cancer.
@en
prefLabel
Detection and monitoring of ovarian cancer.
@en
P2093
P1433
P1476
Detection and monitoring of ovarian cancer.
@en
P2093
Whitney S Graybill
Yusheng Zhu
Zengliu Su
P304
P356
10.1016/J.CCA.2012.10.058
P577
2012-11-16T00:00:00Z